Search Results - "Deville, J.L."

Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? by Sabatier, R., Eymard, J.C., Walz, J., Deville, J.L., Narbonne, H., Boher, J.M., Salem, N., Marcy, M., Brunelle, S., Viens, P., Bladou, F., Gravis, G.

“…Sunitinib is a standard of care for metastatic renal cell carcinoma (mRCC). Hypothyroidism is frequently observed under sunitinib therapy. This study was…”
Get full text

Clinical Activity of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma (Mrcc) – Results of the Resume Study by Oudard, S., Goupil, M. Gross, Geoffrois, L., Guillot, A., Chevreau, C., Deville, J.L., Falkowski, S., Boyle, H., Palmaro, M. Baciuchka, Gimel, P., Laguerre, B., Laramas, M., Pfister, C., Topard, D., Rolland, F., Legouffe, E., Amela, E., Abadie-Lacourtoisie, S., Mahi, N.

Get full text

816PDCLINICAL ACTIVITY OF SUNITINIB RECHALLENGE IN METASTATIC RENAL CELL CARCINOMA (MRCC) – RESULTS OF THE RESUME STUDY by Oudard, S., Goupil, M. Gross, Geoffrois, L., Guillot, A., Chevreau, C., Deville, J.L., Falkowski, S., Boyle, H., Palmaro, M. Baciuchka, Gimel, P., Laguerre, B., Laramas, M., Pfister, C., Topard, D., Rolland, F., Legouffe, E., Amela, E., Abadie-Lacourtoisie, S., Mahi, N.

“…Abstract Aim: Sunitinib is a front-line standard of care in mRCC patients. Several studies have shown that a 2nd line with a TKI after sunitinib progression is…”
Get full text